Xiang Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiang Ren has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Li Kong
Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China
9 shared publications Maryam Chudhary
Department of Histology and Embryology, Dalian Medical University
5 shared publicationsShiyu Song
Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
4 shared publicationsLimin Wei
Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University
3 shared publicationsWenkang Dong
Department of Histology and Embryology, Dalian Medical University
3 shared publications- Wenkang Dong
Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China
3 shared publications
Latest Publications
- 12 August 2026
- Published by Taylor & Francis in Current Eye Research
- p. 1-13
Ginkgo Biloba Standardized Extract EGb 761 Reduces Light and Toxin-Induced Photoreceptor Cell Damage via Regulating Oxidative Stress and Autophagy
Retinal degeneration (RD) refers to a group of vision-threatening disorders and leads to gradual vision loss or permanent vision impairment. It mainly includes age-related macular degeneration and ...
- 12 August 2026
- Published by Taylor & Francis in Current Eye Research
- p. 1-13
Ginkgo Biloba Standardized Extract EGb 761 Reduces Light and Toxin-Induced Photoreceptor Cell Damage via Regulating Oxidative Stress and Autophagy
Retinal degeneration (RD) refers to a group of vision-threatening disorders and leads to gradual vision loss or permanent vision impairment. It mainly includes age-related macular degeneration and ...
- Open Access
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1747872
Upregulation of Trx alleviated high-glucose-induced Müller cell pyroptosis through ASK-1/Cav-1-mediated endoplasmic reticulum stress and autophagy
Objectives: Diabetic retinopathy (DR) is a vision-threatening complication of diabetes. A high-glucose state induces endoplasmic reticulum stress (ERS) and autophagy in retinal Müller cells and further triggers pyroptosis, which ultimately promotes the progression of DR. Apoptosis signal-regulating kinase 1 (ASK1) and caveolin-1 (Cav-1) have been found to be closely associated with ERS and autophagy. Thioredoxin (Trx), a small-molecule protein, is essential for regulating cellular function. However, the regulatory mechanisms linking these molecules are not fully understood in DR. In this study, we investigated the role and mechanism of Trx in alleviating high-glucose-induced pyroptosis in Müller cells. Study design: Serum samples from patients with diabetes, diabetic mice, and Müller cells were used in the study. Results: In vivo and in vitro , high glucose can lead to increased expression of retinal inflammatory factors, morphological damage, and induction of cell pyroptosis. After high-glucose treatment, the expression of ERS- and pyroptosis-related genes increased. This process was reversed after Trx overexpression. Furthermore, autophagy was activated, and the number of TUNEL-positive cells decreased. These effects were reversed by Cav-1 inhibitor treatment. Conclusions: Trx overexpression could delay high-glucose-induced Müller cell pyroptosis by regulating ERS and autophagy via ASK-1/Cav-1, providing a new therapeutic target for DR treatment.
- 27 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1747872
Open AccessUpregulation of Trx alleviated high-glucose-induced Müller cell pyroptosis through ASK-1/Cav-1-mediated endoplasmic reticulum stress and autophagy
Objectives: Diabetic retinopathy (DR) is a vision-threatening complication of diabetes. A high-glucose state induces endoplasmic reticulum stress (ERS) and autophagy in retinal Müller cells and further triggers pyroptosis, which ultimately promotes the progression of DR. Apoptosis signal-regulating kinase 1 (ASK1) and caveolin-1 (Cav-1) have been found to be closely associated with ERS and autophagy. Thioredoxin (Trx), a small-molecule protein, is essential for regulating cellular function. However, the regulatory mechanisms linking these molecules are not fully understood in DR. In this study, we investigated the role and mechanism of Trx in alleviating high-glucose-induced pyroptosis in Müller cells. Study design: Serum samples from patients with diabetes, diabetic mice, and Müller cells were used in the study. Results: In vivo and in vitro , high glucose can lead to increased expression of retinal inflammatory factors, morphological damage, and induction of cell pyroptosis. After high-glucose treatment, the expression of ERS- and pyroptosis-related genes increased. This process was reversed after Trx overexpression. Furthermore, autophagy was activated, and the number of TUNEL-positive cells decreased. These effects were reversed by Cav-1 inhibitor treatment. Conclusions: Trx overexpression could delay high-glucose-induced Müller cell pyroptosis by regulating ERS and autophagy via ASK-1/Cav-1, providing a new therapeutic target for DR treatment.
- Open Access
- 4 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5369
Txnip/Trx Is a Potential Element in Regulating O-GlcNAc Modification in Photoreceptors to Alleviate Diabetic Retinopathy
Hyperglycemia is a key factor in diabetic retinopathy which leads to blindness. O-linked-N-acetylglucosamine (O-GlcNAc) modification changes are linked to various diseases, including diabetic retinopathy. This research aims to study the roles of Txnip and Trx in influencing O-GlcNAc in photoreceptor cells during diabetic retinopathy. A diabetic mouse model and 661w cells, after exposure to high glucose, were employed as models. H&E staining and ERG were used to evaluate the morphology and function of the retina, respectively. Western blotting was used to analyze protein expression, a TUNEL assay was used to measure apoptosis, and a co-immunoprecipitation (CO-IP) assay was used to detect the interactions of protein. In diabetic mice, electroretinogram (ERG) amplitude wave, retinal thickness, and body weight decreased. Glial fibrillary acidic protein (GFAP), Iba1 expression, and blood glucose level increased. In vitro, the percentage of apoptotic cell, Bax, and caspase3 levels increased, and Bcl2 decreased in 661w cells under high-glucose conditions. Moreover, Txnip expression was upregulated, while Trx was downregulated. Additionally, a Western blot analysis revealed that high-glucose exposure led to increased O-GlcNAc modification both in vivo and in vitro. The CO-IP results show that Txnip interacted with O-GlcNAc modifications. S-opsin expression was significantly downregulated in vitro under high-glucose conditions. Knockdown Txnip or upregulation Trx could reverse or delay apoptosis in 661w cells under hyperglycemic conditions. Txnip/Trx is a potential element in regulating photoreceptor apoptosis in diabetic retinopathy. The underlying mechanism is linked to regulation of O-GlcNAc modification in photoreceptor cells in DR.
- 4 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5369
Open AccessTxnip/Trx Is a Potential Element in Regulating O-GlcNAc Modification in Photoreceptors to Alleviate Diabetic Retinopathy
Hyperglycemia is a key factor in diabetic retinopathy which leads to blindness. O-linked-N-acetylglucosamine (O-GlcNAc) modification changes are linked to various diseases, including diabetic retinopathy. This research aims to study the roles of Txnip and Trx in influencing O-GlcNAc in photoreceptor cells during diabetic retinopathy. A diabetic mouse model and 661w cells, after exposure to high glucose, were employed as models. H&E staining and ERG were used to evaluate the morphology and function of the retina, respectively. Western blotting was used to analyze protein expression, a TUNEL assay was used to measure apoptosis, and a co-immunoprecipitation (CO-IP) assay was used to detect the interactions of protein. In diabetic mice, electroretinogram (ERG) amplitude wave, retinal thickness, and body weight decreased. Glial fibrillary acidic protein (GFAP), Iba1 expression, and blood glucose level increased. In vitro, the percentage of apoptotic cell, Bax, and caspase3 levels increased, and Bcl2 decreased in 661w cells under high-glucose conditions. Moreover, Txnip expression was upregulated, while Trx was downregulated. Additionally, a Western blot analysis revealed that high-glucose exposure led to increased O-GlcNAc modification both in vivo and in vitro. The CO-IP results show that Txnip interacted with O-GlcNAc modifications. S-opsin expression was significantly downregulated in vitro under high-glucose conditions. Knockdown Txnip or upregulation Trx could reverse or delay apoptosis in 661w cells under hyperglycemic conditions. Txnip/Trx is a potential element in regulating photoreceptor apoptosis in diabetic retinopathy. The underlying mechanism is linked to regulation of O-GlcNAc modification in photoreceptor cells in DR.
- Open Access
- 6 November 2024
- Published by Elsevier in Life Sciences
- Vol. 359, 123223
Oxidative and endoplasmic reticulum stress in diabetes-related hearing loss: Protective effects of thioredoxin
- 6 November 2024
- Published by Elsevier in Life Sciences
- Vol. 359, 123223
Open AccessOxidative and endoplasmic reticulum stress in diabetes-related hearing loss: Protective effects of thioredoxin
- Open Access
- 6 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6286
O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy
Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.
- 6 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (11) , 6286
Open AccessO-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy
Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.
- 13 February 2023
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (3) , 421-433
Thioredoxin 1 overexpression attenuated diabetes‐induced endoplasmic reticulum stress in Müller cells via apoptosis signal‐regulating kinase 1
As one of the common and serious chronic complications of diabetes mellitus (DM), the related mechanism of diabetic retinopathy (DR) has not been fully understood. Müller cell reactive gliosis is one of the early pathophysiological features of DR. Therefore, exploring the manner to reduce diabetes‐induced Müller cell damage is essential to delay DR. Thioredoxin 1 (Trx1), one of the ubiquitous redox enzymes, plays a vital role in redox homeostasis via protein–protein interactions, including apoptosis signal‐regulating kinase 1 (ASK1). Previous studies have shown that upregulation of Trx by some drugs can attenuate endoplasmic reticulum stress (ERS) in DR, but the related mechanism was unclear. In this study, we used DM mouse and high glucose (HG)‐cultured human Müller cells as models to clarify the effect of Trx1 on ERS and the underlying mechanism. The data showed that the diabetes‐induced Müller cell damage was increased significantly. Moreover, the expression of ERS and reactive gliosis was also upregulated in diabetes in vivo and in vitro. However, it was reversed after Trx1 overexpression. Besides, ERS‐related protein expression, reactive gliosis, and apoptosis were decreased after transfection with ASK1 small‐interfering RNA in stable Trx1 overexpression Müller cells after HG treatment. Taken together, Trx1 could protect Müller cells from diabetes‐induced damage, and the underlying mechanism was related to inhibited ERS via ASK1.
- 13 February 2023
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (3) , 421-433
Thioredoxin 1 overexpression attenuated diabetes‐induced endoplasmic reticulum stress in Müller cells via apoptosis signal‐regulating kinase 1
As one of the common and serious chronic complications of diabetes mellitus (DM), the related mechanism of diabetic retinopathy (DR) has not been fully understood. Müller cell reactive gliosis is one of the early pathophysiological features of DR. Therefore, exploring the manner to reduce diabetes‐induced Müller cell damage is essential to delay DR. Thioredoxin 1 (Trx1), one of the ubiquitous redox enzymes, plays a vital role in redox homeostasis via protein–protein interactions, including apoptosis signal‐regulating kinase 1 (ASK1). Previous studies have shown that upregulation of Trx by some drugs can attenuate endoplasmic reticulum stress (ERS) in DR, but the related mechanism was unclear. In this study, we used DM mouse and high glucose (HG)‐cultured human Müller cells as models to clarify the effect of Trx1 on ERS and the underlying mechanism. The data showed that the diabetes‐induced Müller cell damage was increased significantly. Moreover, the expression of ERS and reactive gliosis was also upregulated in diabetes in vivo and in vitro. However, it was reversed after Trx1 overexpression. Besides, ERS‐related protein expression, reactive gliosis, and apoptosis were decreased after transfection with ASK1 small‐interfering RNA in stable Trx1 overexpression Müller cells after HG treatment. Taken together, Trx1 could protect Müller cells from diabetes‐induced damage, and the underlying mechanism was related to inhibited ERS via ASK1.
- Open Access
- 15 September 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 24 (5) , 1-10
Role of Takeda G protein‑coupled receptor 5 in microvascular endothelial cell dysfunction in diabetic retinopathy (Review)
Diabetic retinopathy (DR) is a frequent microvascular complication of advanced‑stage diabetes. Endothelial cell dysfunction (ED) induced by diabetes plays an important role in the development of DR. It is considered that inflammation and mitochondrial homeostasis are associated with the progression of ED. Takeda G protein‑coupled receptor 5 (TGR5) is a membrane receptor for bile acids (BAs) that plays an important role in regulating BA metabolism. Recent studies have shown that TGR5 is involved in regulating various mediators of ED and improving the dysfunction of vascular endothelial cells in DR; however, the exploration of specific related mechanisms remains an active research area in this field, which suggests that TGR5 may be one of the potential targets for the treatment of associated ED in DR. In the present review, the association between TGR5 and mitochondrial homeostasis was investigated. The extent of inflammation in DR‑induced ED was assessed to provide possible evidence for the development of targeted therapies against DR.
- 15 September 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 24 (5) , 1-10
Open AccessRole of Takeda G protein‑coupled receptor 5 in microvascular endothelial cell dysfunction in diabetic retinopathy (Review)
Diabetic retinopathy (DR) is a frequent microvascular complication of advanced‑stage diabetes. Endothelial cell dysfunction (ED) induced by diabetes plays an important role in the development of DR. It is considered that inflammation and mitochondrial homeostasis are associated with the progression of ED. Takeda G protein‑coupled receptor 5 (TGR5) is a membrane receptor for bile acids (BAs) that plays an important role in regulating BA metabolism. Recent studies have shown that TGR5 is involved in regulating various mediators of ED and improving the dysfunction of vascular endothelial cells in DR; however, the exploration of specific related mechanisms remains an active research area in this field, which suggests that TGR5 may be one of the potential targets for the treatment of associated ED in DR. In the present review, the association between TGR5 and mitochondrial homeostasis was investigated. The extent of inflammation in DR‑induced ED was assessed to provide possible evidence for the development of targeted therapies against DR.
- Open Access
- 9 August 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 957667
Thioredoxin-interacting protein in diabetic retinal neurodegeneration: A novel potential therapeutic target for diabetic retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes mellitus and has been considered a microvascular disease for a long time. However, recent evidence suggests that diabetic retinal neurodegeneration (DRN), which manifests as neuronal apoptosis, a decrease in optic nerve axons, and reactive gliosis, occurs prior to retinal microvascular alterations. Thioredoxin-interacting protein (TXNIP) is an endogenous inhibitor of thioredoxin (Trx), and it acts by inhibiting its reducing capacity, thereby promoting cellular oxidative stress. In addition, it participates in regulating multiple signaling pathways as a member of the α-arrestin family of proteins. Accumulating evidence suggests that TXNIP is upregulated in diabetes and plays a pivotal role in the pathophysiological process of DR. In this review, we summarized the role of TXNIP in DRN, aiming to provide evidence for DR treatment in the future.
- 9 August 2022
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 16, 957667
Open AccessThioredoxin-interacting protein in diabetic retinal neurodegeneration: A novel potential therapeutic target for diabetic retinopathy
Diabetic retinopathy (DR) is a common complication of diabetes mellitus and has been considered a microvascular disease for a long time. However, recent evidence suggests that diabetic retinal neurodegeneration (DRN), which manifests as neuronal apoptosis, a decrease in optic nerve axons, and reactive gliosis, occurs prior to retinal microvascular alterations. Thioredoxin-interacting protein (TXNIP) is an endogenous inhibitor of thioredoxin (Trx), and it acts by inhibiting its reducing capacity, thereby promoting cellular oxidative stress. In addition, it participates in regulating multiple signaling pathways as a member of the α-arrestin family of proteins. Accumulating evidence suggests that TXNIP is upregulated in diabetes and plays a pivotal role in the pathophysiological process of DR. In this review, we summarized the role of TXNIP in DRN, aiming to provide evidence for DR treatment in the future.
- Open Access
- 5 August 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (8) , 725
O-GlcNAc Modification and Its Role in Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading complication in type 1 and type 2 diabetes and has emerged as a significant health problem. Currently, there are no effective therapeutic strategies owing to its inconspicuous early lesions and complex pathological mechanisms. Therefore, the mechanism of molecular pathogenesis requires further elucidation to identify potential targets that can aid in the prevention of DR. As a type of protein translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification is involved in many diseases, and increasing evidence suggests that dysregulated O-GlcNAc modification is associated with DR. The present review discusses O-GlcNAc modification and its molecular mechanisms involved in DR. O-GlcNAc modification might represent a novel alternative therapeutic target for DR in the future.
- 5 August 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (8) , 725
Open AccessO-GlcNAc Modification and Its Role in Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading complication in type 1 and type 2 diabetes and has emerged as a significant health problem. Currently, there are no effective therapeutic strategies owing to its inconspicuous early lesions and complex pathological mechanisms. Therefore, the mechanism of molecular pathogenesis requires further elucidation to identify potential targets that can aid in the prevention of DR. As a type of protein translational modification, O-linked β-N-acetylglucosamine (O-GlcNAc) modification is involved in many diseases, and increasing evidence suggests that dysregulated O-GlcNAc modification is associated with DR. The present review discusses O-GlcNAc modification and its molecular mechanisms involved in DR. O-GlcNAc modification might represent a novel alternative therapeutic target for DR in the future.